Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Baxter
Moodys
US Army
Teva
Dow
Colorcon
Boehringer Ingelheim
Covington

Generated: July 21, 2018

DrugPatentWatch Database Preview

MEGACE ES Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

Which patents cover Megace Es, and when can generic versions of Megace Es launch?

Megace Es is a drug marketed by Endo Pharms Inc and is included in one NDA. There are six patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and ninety-seven patent family members in twenty-eight countries.

The generic ingredient in MEGACE ES is megestrol acetate. There are eighteen drug master file entries for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the megestrol acetate profile page.
Drug patent expirations by year for MEGACE ES
Pharmacology for MEGACE ES
Ingredient-typeProgesterone Congeners
Drug ClassProgestin
Medical Subject Heading (MeSH) Categories for MEGACE ES
Synonyms for MEGACE ES
(1S,2R,10R,11S,14R,15S)-14-ACETYL-2,8,15-TRIMETHYL-5-OXOTETRACYCLO[8.7.0.0(2),?.0(1)(1),(1)?]HEPTADECA-6,8-DIEN-14-YL ACETATE
(8R,9S,10R,13S,14S,17R)-17-acetyl-6,10,13-trimethyl-3-oxo-2,3,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl acetate
[(8R,9S,10R,13S,14S,17R)-17-acetyl-6,10,13-trimethyl-3-oxo-2,8,9,11,12,14,15,16-octahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate
14365-EP2311464A1
14365-EP2316836A1
17-(acetyloxy)-6-methylpregna-4,6-diene-3,20-dione
17-Acetoxy-6-methylpregna-4,20-dione
17-Acetoxy-6-methylpregna-4,6-diene-3,20-dione
17-alpha-Acetoxy-6-dehydro-6-methylprogesterone
17-Hydroxy-6-methylpregna-4,20-dione acetate
17-Hydroxy-6-methylpregna-4,6-diene-3,20-dione 17-acetate
17-Hydroxy-6-methylpregna-4,6-diene-3,20-dione acetate
17.alpha.-Acetoxy-6-dehydro-6-methylprogesterone
17.alpha.-Acetoxy-6-methyl-4,20-dione
17.alpha.-Acetoxy-6-methylpregna-4,20-dione
17alpha-Acetoxy-6-dehydro-6-methylprogesterone
17alpha-Acetoxy-6-methylpregna-4,6-diene-3,20-dione
17alpha-Hydroxy-6-methylpregna-4,6-diene-3,20-dione acetate
51154-23-5
595-33-5
595M335
6-Dehydro-6-methyl-17-alpha-acetoxyprogesterone
6-Dehydro-6-methyl-17.alpha.-acetoxyprogesterone
6-Dehydro-6-methyl-17alpha-acetoxyprogesterone
6-Methyl-17-alpha-acetoxypregna-4,6-diene-3,20-dione
6-Methyl-17-alpha-hydroxy-delta(sup 6)-progesterone acetate
6-Methyl-17.alpha.-hydroxy-.delta.(sup 6)-progesterone acetate
6-Methyl-17alpha-hydroxy-delta(sup 6)-progesterone acetate
6-Methyl-3,20-dioxopregna-4,6-dien-17-yl acetate
6-Methyl-6-dehydro-17-alpha-acetoxyprogesterone
6-Methyl-6-dehydro-17.alpha.-acetoxyprogesterone
6-Methyl-6-dehydro-17.alpha.-acetylprogesterone
6-Methyl-6-dehydro-17alpha-acetoxyprogesterone
6-Methyl-delta(sup 4,6)-pregnadien-17-alpha-ol-3,20-dione acetate
6-Methyl-delta(sup 6)-dehydro-17-alpha-acetoxyprogesterone
6-Methyl-delta4,6-pregnadien-17alpha-ol-3,20-dione acetate
AB00383046_16
AB00383046-13
AB00383046-14
AB00383046-15
AB00490013
AB2000040
AC-24570
AC1L1XW9
AJ-47998
AK145584
AKOS015894927
Ambap595-33-5
AN-21566
ANW-43468
API0003279
AS-13384
B1377
BCP9000904
BCPP000168
BDH 1298
BDH-1298
BDH-1298, NSC-71423
BPBio1_001048
BRD-K19507340-001-03-1
BSPBio_000952
C08151
CAS-595-33-5
CCG-100899
CCRIS 372
CHEMBL1201139
CS-2065
CTK5B0088
D00952
DSSTox_CID_20683
DSSTox_GSID_40683
DSSTox_RID_79539
DTXSID9040683
EINECS 209-864-5
HMS1570P14
HMS2051I20
HMS2090N04
HMS2097P14
HMS2235D16
HY-13676
I040
LMST02030118
LS-118489
Magestin
Megace
Megace;Megace ES
Megeron
Megesgtrol Acetate, pharmaceutical secondary standard; traceable to USP, PhEur and BP
Megestat
Megestrol (Acetate)
MEGESTROL ACETATE
Megestrol acetate (USAN)
Megestrol acetate [USAN:USP]
Megestrol acetate [USAN]
Megestrol acetate for peak identification, European Pharmacopoeia (EP) Reference Standard
Megestrol acetate for system suitability, European Pharmacopoeia (EP) Reference Standard
Megestrol acetate, analytical standard, for drug analysis
Megestrol acetate, European Pharmacopoeia (EP) Reference Standard
Megestrol acetate, United States Pharmacopeia (USP) Reference Standard
Megestrol acetate, VETRANAL(TM), analytical standard
Megestrol acetole
Megestrol acetole [Progestins]
Megestrol-17-acetate
MegestrolAcetate
Megestryl acetate
MFCD00056470
MLS000028633
MLS000759501
MLS001074091
MLS001424055
MolPort-005-934-820
NC00149
NCGC00016516-01
NCGC00024196-03
NCGC00024196-05
NCGC00255456-01
Niagestin
NSC-71423
NSC71423
Opera_ID_1511
Ovaban
Ovaban (Veterinary)
Ovarid
Pallace
par-100,2
PL057943
Pregna-4,20-dione, 17-(acetyloxy)-6-methyl-
Pregna-4,20-dione, 17-hydroxy-6-methyl-, acetate
Pregna-4,6-diene-3,20-dione, 17-(acetyloxy)-6-methyl-
Pregna-4,6-diene-3,20-dione, 17-hydroxy-6-methyl-, acetate
Prestwick0_000956
Prestwick1_000956
Prestwick2_000956
Prestwick3_000956
Q-201346
RQZAXGRLVPAYTJ-GQFGMJRRSA-N
s1304
SC 10363
SC-10363
SC-16134
SC10363
SCHEMBL745
SMR000058691
SPBio_003101
TJ2M0FR8ES
Tox21_110469
Tox21_110469_1
Tox21_302360
TR-031797
UNII-TJ2M0FR8ES
WLN: L E5 B666 OV KU MUTJ A1 E1 FV1 FOV1 L1
ZINC4097467

US Patents and Regulatory Information for MEGACE ES

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Endo Pharms Inc MEGACE ES megestrol acetate SUSPENSION;ORAL 021778-001 Jul 5, 2005 AB RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Endo Pharms Inc MEGACE ES megestrol acetate SUSPENSION;ORAL 021778-001 Jul 5, 2005 AB RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Endo Pharms Inc MEGACE ES megestrol acetate SUSPENSION;ORAL 021778-001 Jul 5, 2005 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Endo Pharms Inc MEGACE ES megestrol acetate SUSPENSION;ORAL 021778-001 Jul 5, 2005 AB RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Paragraph IV (Patent) Challenges for MEGACE ES
Drugname Dosage Strength RLD Date
➤ Subscribe Oral Suspension 125 mg/mL ➤ Subscribe ➤ Sign Up

Non-Orange Book US Patents for MEGACE ES

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,521,068 Dry powder aerosols of nanoparticulate drugs ➤ Sign Up
8,293,277 Controlled-release nanoparticulate compositions ➤ Sign Up
6,969,529 Nanoparticulate compositions comprising copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers ➤ Sign Up
8,652,464 Method of treatment using nanoparticulate compositions having lysozyme as a surface stabilizer ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Cerilliant
Teva
Accenture
Moodys
Express Scripts
Deloitte
AstraZeneca
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.